Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Milestone Pharmaceuticals (NASDAQ:MIST) to a strong-buy rating in a report issued on Thursday morning,Zacks.com reports.

Other analysts also recently issued research reports about the stock. Zacks Research downgraded shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 24th. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Milestone Pharmaceuticals in a report on Tuesday, January 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. TD Cowen raised shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, December 15th. Finally, Wall Street Zen downgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Milestone Pharmaceuticals Stock Up 0.5%

Shares of NASDAQ MIST opened at $2.02 on Thursday. Milestone Pharmaceuticals has a 12-month low of $0.71 and a 12-month high of $3.06. The company has a market capitalization of $237.69 million, a PE ratio of -2.56 and a beta of 0.69. The company has a debt-to-equity ratio of 1.37, a current ratio of 8.01 and a quick ratio of 7.96. The firm’s 50-day moving average is $1.63 and its two-hundred day moving average is $1.94.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Friday, March 20th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $1.44 million during the quarter, compared to analysts’ expectations of $37.52 million. Equities analysts anticipate that Milestone Pharmaceuticals will post -0.62 EPS for the current fiscal year.

Insider Activity

In related news, CEO Joseph Oliveto sold 34,523 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39. Following the transaction, the chief executive officer owned 482,744 shares of the company’s stock, valued at approximately $931,695.92. This represents a 6.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 70,193 shares of company stock worth $135,472 over the last quarter. Corporate insiders own 19.50% of the company’s stock.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the company. Creative Planning lifted its stake in shares of Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after buying an additional 10,000 shares during the period. Raymond James Financial Inc. lifted its stake in shares of Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after buying an additional 10,000 shares during the period. Bay Rivers Group raised its stake in Milestone Pharmaceuticals by 72.9% during the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after purchasing an additional 12,170 shares during the period. Sapient Capital LLC purchased a new position in Milestone Pharmaceuticals during the third quarter worth approximately $25,000. Finally, Strategic Family Wealth Counselors L.L.C. purchased a new position in Milestone Pharmaceuticals during the fourth quarter worth approximately $25,000. Hedge funds and other institutional investors own 86.18% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.